Novo Nordisk earned approval for a daily oral version of semaglutide (Rybelsus) in T2D (NCT02906930)
Semaglutide once weekly for treatment of obesity. Nature Reviews Endocrinology .
13.7% | Eli Lilly and Company, accessed April 23, 2025, How to Use, Dosing & Side Effects | Mounjaro (tirzepatide) - Eli Lilly, accessed April 23, 2025, Mounjaro (tirzepatide) Injection: The First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes | Eli Lilly and Company, accessed April 23, 2025, Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight, accessed April 23, 2025, Why you're not losing weight on Zepbound
Whether youre looking to shed stubborn pounds, improve overall health, or boost your energy levels, our medically guided weight loss programs are designed to deliver sustainable, long-term results